Hmmm, so which biotech companies that you follow consider FoBs germane to their business? How many of their drugs will be vulnerable to Biosimilars in the next few years?
As an example, in your area I am thinking Genzyme and its niche drugs which BP may consider too small a market for their mega manufacturing capabilities to bother with.
Market Data 
Markets 
AI
